News Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Delayed Nasdaq Stockholm Other stock markets 10:59:45 10/09/2024 BST			5-day change	1st Jan Change
27.80 ^SEK	-2.11%		-3.47%	-22.35%

08-29	First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	CI
08-27	Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	MT

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guard Therapeutics publishes prospectus due to upcoming rights issue	09-02	AQ
First patient dosed in Guard Therapeutics’ phase 2b study POINTER	08-29	AQ
First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER	08-29	CI
Guard Therapeutics Plans New SEK80 Million Rights Issue to Fund Kidney Drug Study	08-27	MT
Guard Therapeutics carries out announced rights issue (repair issue)	08-27	AQ
Guard Therapeutics International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-22	CI
Guard Therapeutics receives regulatory EU approvals to include patients in its Phase 2b study POINTER	08-08	AQ
Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter	08-08	CI
Guard Therapeutics carries out a directed share issue of approximately SEK 60 million and intends to carry out a repair issue	06-17	AQ
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology	05-27	AQ
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035	05-27	CI
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Guard Therapeutics International AB announced that it expects to receive SEK 59.99074 million in funding from Swedbank Robur Fonder AB, Industrifonden, Strand Kapitalforvaltning AB and another investor	05-07	CI
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER	04-15	AQ
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	04-15	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-21	CI
Guard Therapeutics presented development strategy and new preclinical results at R&D Update	01-31	AQ
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	01-31	CI
Invitation to Guard Therapeutics’ R&D Update on January 30	01-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Guard Therapeutics International AB

Equities

GUARD

SE0021181559

Filters